MAPP
MAP Pharmaceuticals, Inc.NASDAQ
MAPP is defunct since March 4, 2013. acquired by a private company
  • Mar. 1, 2013, 3:18 PM

    Allergan (AGN +0.2%) shares tick higher after reporting the expiration of its tender offer to purchase all of the outstanding common shares of MAP Pharmaceuticals (MAPP) for $25 per share. The tender offer acquired about 75.1% of all outstanding shares, satisfying a majority. In order to complete a short-form merger, AGN says it will exercise a top-up option in which it will purchase newly issued shares in order to own one share more than 90% of shares outstanding. Separately, Wedbush cuts the shares to Neutral on the news.

    | Mar. 1, 2013, 3:18 PM
  • Jan. 23, 2013, 12:45 PM
    Midday top 10 gainers: MAPP +59%. HMNF +34%. JAXB +26%. CREE +19%. DQ +18%. THLD +16%. KERX +15%. SMCI +15%. SILC +14%. FSGI +14%.
    Midday top 10 Losers: STRI -25%. COH -15%. NMRX -15%. STSI -14%. URRE -12%. FU -12%. IAG -11%. GVP -10%. TTM -10%. VLTR -10%.
    | Jan. 23, 2013, 12:45 PM
  • Jan. 23, 2013, 9:10 AM
    Premarket gainers: MAPP +59%. TELK +23%. CREE +14%. ISRG +9%. RFMD +6%. ACAD +6%. GOOG +5%.
    Losers: COH -17%. MCP -14%. NMRX -14%. STSI -11%. BNNY -8%. GD -5%
    | Jan. 23, 2013, 9:10 AM | 1 Comment
  • Jan. 22, 2013, 10:45 PM

    Allergan (AGN) agrees to acquire MAP Pharmaceuticals (MAPP) for $958M ($25/share) in cash, a 60% premium over MAP's Tuesday close. MAP's experimental migraine drug Levadex is set to receive a regulatory decision by April 15; Botox maker Allergan (which already had rights to help market Levadex) is showing confidence in an OK by taking total control.

    | Jan. 22, 2013, 10:45 PM | 1 Comment
  • Nov. 23, 2012, 1:21 PM
    Shares of MAP Pharmaceuticals (MAPP) soared today, finishing up over +20% after the company announced that the FDA accepted its Levadex resubmission with a six-month review.
    | Nov. 23, 2012, 1:21 PM
  • Nov. 23, 2012, 12:45 PM
    Midday top 10 gainers: CCCL +42%. MAPP +21%. BGMD +21%. MCP +18%. INUV +16%. FIZZ +15%. ROSG +14%. DAC +13%. RIMM +13%. RIC +12%.
    Top 10 Losers: KITD -64%. PTGI -17%. SGOC -12%. HDSN -9%. TELK -9%. SAB -8%. HRT -8%. NFEC -8%. THQI -7%. RCON -7%.
    | Nov. 23, 2012, 12:45 PM | 1 Comment
  • Nov. 23, 2012, 9:10 AM
    Premarket gainers: ALU +18%. MAPP +14%. RIMM +11%. CIG +10%. SBS +7%. NBG +5%.
    Losers: KITD -55.56%.
    | Nov. 23, 2012, 9:10 AM | 1 Comment
  • Nov. 21, 2012, 7:15 PM

    MAP Pharmaceuticals (MAPP) says its new drug application resubmission for Levadex, an orally inhaled drug for the potential treatment of acute migraine, has been accepted for filing by the FDA. The FDA has classified the resubmission as a complete, Class 2 response to the FDA's March 26 action letter and has set a goal date of April 15, 2013 under the prescription drug user fee act.

    | Nov. 21, 2012, 7:15 PM
  • Aug. 1, 2012, 1:55 PM

    Shares of MAP Pharmaceuticals (MAPP -5.3%) slide today after the company priced its secondary offering of 3.88M shares at $13.40, a 5% discount to yesterday's close. The company intends to use the proceeds to bring its investigational migraine drug Levadex to market, as well as for other general corporate purposes.

    | Aug. 1, 2012, 1:55 PM
  • Aug. 1, 2012, 9:15 AM
    Premarket gainers: SIMG +28%. LH +13%. BPI +12%. VG +9%. GNW +8%. FTR +7%. PC +7%. GRMN +6%. DGX +6%.
    Losers: CECO -20%. DRIV -17%. TRLG -15%. ARRY -13%. NICE -13%. ENR -10%. HZNP -9%. DWA -7%. SAVE -6%. IDIX -6%. MAPP -6%. STP -5%.
    | Aug. 1, 2012, 9:15 AM
  • Jun. 25, 2012, 10:58 AM

    MAP Pharmaceuticals (MAPP -1.2%) intends to refile its new-drug application for its Levadex migraine treatment later this year after meeting with the FDA, which had expressed concerns about manufacturing problems. MAP believes these problems have been resolved and it won't need to carry out new studies. (PR)

    | Jun. 25, 2012, 10:58 AM
  • Apr. 13, 2012, 11:17 AM

    Map Pharmaceuticals (MAPP -2.7%) says it plans to meet with the FDA during the current quarter to discuss manufacturing issues that are hindering the approval of its migraine medication Levadex.

    | Apr. 13, 2012, 11:17 AM
  • Mar. 27, 2012, 9:03 AM

    Premarket gainers: OPXT +55%. WNC +9%. ISTA +8%. DANG +5%. RBS +3%. ARNA +3%. LEN +3%.
    Losers: MAPP -17%. MMR -16%. APOL -6%. NBG -6%. TOT -6%. OCLR -3%. EXPE -3%. HEK -3%. EXXI -3%.

    | Mar. 27, 2012, 9:03 AM
  • Mar. 27, 2012, 8:34 AM

    JPMorgan tries to make sense out of all the drama with MAP Pharmaceuticals (MAPP), by taking the long view that Levadex is an "attractive, approvable product" despite missing out on first-pass FDA approval. Shares have been on a roller coaster ride since the FDA issued a complete response letter after the market closed yesterday, sitting as high as +7% and as low as -30% before settling back to trade -18.3% premarket. Stay tuned.

    | Mar. 27, 2012, 8:34 AM
  • Mar. 27, 2012, 7:28 AM

    Shares of MAP Pharmaceuticals (MAPP) nosedive after coming off of a trading halt and are now down 28.8% after ringing up a tidy AH gain yesterday. Though the company landed FDA approval for Levadex, a number of questions concerning its disclosures and ability to bring the migraine treatment to the market still linger.

    | Mar. 27, 2012, 7:28 AM
  • Mar. 26, 2012, 8:40 PM

    MAP Pharmaceuticals (MAPP) says the FDA has issued a Complete Response letter to its New Drug Application for Levadex. The FDA didn't cite clinical safety or efficacy issues, nor request any additional clinical studies be conducted prior to approval. It did however, request the company address issues relating to chemistry, manufacturing and controls and observations from a recent facility inspection of a third party manufacturer. Shares +7% AH.

    | Mar. 26, 2012, 8:40 PM | 3 Comments